1206775-52-1

Upstream product

• 185017-72-5 3-bromo-2-chloro-6-methyl pyridine 
• 1206776-81-9 2-methoxy-3-bromo-6-methylpyridine N-oxide 
• 717843-47-5 3-bromo-2-methoxy-6-methylpyridine 
• 1214334-70-9 5-bromo-6-methoxypyridine-2-carboxylic acid 
• 959958-25-9 5-bromo-6-chloropyridine-2-carboxylic acid 
• 1214329-07-3 5-bromo-6-methoxy-pyridine-2-carboxylic acid methyl ester 
• 1206776-83-1 (5-bromo-6-methoxypyridin-2-yl)methanol 

Downstream Products

• 1227582-89-9 6-methoxy-5-phenylpyridine-2-carbaldehyde 

Relevant academic research and scientific papers

SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS

Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

Synthesis method of 6-(difluoromethyl)-2-hydroxypyridine-3-sulfonyl chloride

The invention provides a synthetic method of 6-(difluoromethyl)-2-hydroxypyridine-3-sulfonyl chloride, and belongs to the field of organic chemical synthesis. According to the synthetic method, 2-methoxy-3-bromo-6-methylpyridine is used as an initial raw

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES

The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.

2-PYRIDONE COMPOUNDS

A 2-pyridone compound represented by the formula [1]: {wherein in the formula [1], the ring represented by A represents a benzene ring or a pyridine ring, X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, and W represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)}, a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.